Background: The incidence of end stage renal disease (ESRD) in patients with systemic lupus erythematosus (SLE) is rising. However, the relationship between osteoporotic fractures and SLE in the setting of ESRD remains uninvestigated. The purpose of this study was to compare the frequency of incident osteoporotic fractures in patients with ESRD with and without SLE, to identify risk factors for fractures in patients with SLE and ESRD, and to examine the contribution of these fractures to mortality. Methods: Retrospective cohort study of patients with SLE (n ¼ 716) and a 5% random sample of controls without SLE (n ¼ 4176) in the United States Renal Data System (USRDS) from years 2006-2008 enrolled in Medicare Part D. Results: Fractures occurred in 10.6% (n ¼ 76) of patients with SLE and ESRD and 12.1% (n ¼ 507) of patients with ESRD without SLE (p ¼ 0.24). Older age (adjusted relative risk 1.02, 95% confidence interval 1.01-1.04) was associated with an increased risk for fracture in patients with SLE and ESRD. In multivariable analyses, vertebral and hip fractures more than doubled the risk for mortality. Conclusions: The frequency of osteoporotic fractures in patients with SLE and ESRD is similar to the general population of patients with ESRD. Vertebral and hip fractures are significant contributors to mortality in patients with SLE and ESRD. Fracture prevention, in particular, for elderly patients with SLE and ESRD, should be considered. Summary: SLE is not an independent risk factor for fractures in patients with ESRD. However, among patients with SLE and ESRD, vertebral and hip fractures are significant contributors to mortality. Lupus (2018) 27, 17-24.
Introduction
Growing evidence continues to emerge identifying osteoporosis and osteoporotic fractures as significant comorbidities in patients with systemic lupus erythematosus (SLE). 1, 2 The etiology of low bone mineral density (BMD) in SLE is multifactorial and includes chronic inflammation, hormonal factors, medication use, and genetic predisposition. 3, 4 Hip fractures are increasingly recognized as a complication of dialysis, raising concern for similar events among patients with SLE in end stage renal disease (ESRD). Approximately 50% of adults who present with SLE have nephritis, with 10%-30% progressing to ESRD within 15 years. 5, 6 Moreover, the incidence of patients with lupus nephritis increased in the late 2000s, underscoring the need for research addressing osteoporosis in SLE. 7 To our knowledge, no previous investigations have reported the association of SLE and ESRD with osteoporotic fractures.
The purpose of this study was threefold: (1) to compare the frequency of incident osteoporotic fractures in patients with ESRD with and without SLE; (2) to identify risk factors for osteoporotic fractures in patients with SLE and ESRD; and (3) to determine the contribution of fracture to mortality in patients with SLE and ESRD.
Patients and methods

Data sources
Data were obtained from the United States Renal Data System (USRDS), a national registry of patients with chronic kidney disease (CKD) and ESRD that was started in 1988. The USRDS defines ESRD as chronic renal failure requiring renal replacement therapy-dialysis or transplant. In the United States, patients with ESRD of any age are eligible for Medicare. As of 2014, the database contained approximately 2.7 million patients. Datasets consist of de-identified patient health information mostly procured from Medicare claims and data collection forms (e.g. ESRD Medical Evidence Report (CMS 2728) submitted within 45 days of starting renal replacement therapy, ESRD Death Notification (CMS 2746) submitted within 2 weeks of expiration). Together, they profile demographic and diagnoses data, details of dialysis, and inpatient events. The Part D dataset includes information on annual enrollment into the prescription drug program and details on filled prescriptions. An estimated 62% of patients with ESRD in the database are enrolled in Part D. 8 
Patients
Adult patients (age 18 years) who initiated hemodialysis or peritoneal dialysis between calendar years 2006 and 2008 and who survived for at least one year on dialysis from the USRDS database were eligible for inclusion in this analysis. Patients with a prior kidney transplant (V42.0) or with missing or unknown age, race, gender, dialysis type, smoking status, and duration of dialysis were excluded. Data from 246,370 patients were available and followed forward until 31 December 2011.
The International Classification of Diseases, 9th Revision, Clinical Modification (ICD-9) codes were used to identify patients with a diagnosis of SLE (710.0) prior to start of dialysis (n ¼ 1311). Due to the relatively large number of individuals without a diagnosis of SLE (n ¼ 245,054), a 5% sample of these controls was randomly selected (n ¼ 12,339 21 proton pump inhibitors (PPIs), 22 anticonvulsants, 23 thiazide diuretics, 24 loop diuretics, 25, 26 sedatives and hypnotics, 27 oral hypoglycemics [28] [29] [30] ) were examined. Medications used to treat osteoporosis used in the USRDS, including estrogen, selective estrogen receptor modulators (SERMs), parathyroid hormone (PTH), vitamin D and vitamin D analogs, calcium and magnesium supplementation, and bisphosphonates, were also included. Previous fracture was defined as a diagnosis for a non-traumatic fracture (ICD-9) within 5 years prior to start of dialysis. Medication use was ascertained on whether the patient had any filled prescription for the drug during the time period of study using Medicare Part D data. The CCI was calculated using data from ICD-9 codes and medical evidence forms available in the USRDS prior to or on date of initiation of dialysis.
Mortality
Up to five-year all-cause mortality following any incident fracture in patients with SLE was determined and compared to mortality in patients with SLE without fractures during the study period. For those who did not fracture, start date was date of entry into the USRDS. For those who had an incident fracture, the start date was the date of the incident fracture. For those who died, their survival time in months was determined as time from the start date to death. For those who did not die-that is, were considered censored-survival time in months was determined as the time from the start date to their last claim date.
Statistical analyses
The incidence of fractures in patients with ESRD with and without SLE was determined. Descriptive statistics (frequencies and percentages, or means and standard deviations) of each individual risk factor by incident fracture status were determined, and 2 or t-tests were used to examine differences. To examine which potential risk factors were associated with incident fractures among those with SLE (n ¼ 716), generalized linear models were used assuming an underlying Poisson distribution with log link and an offset parameter of the natural log of person years (calculated as time of incident dialysis to time of fracture or last date of follow-up). Each risk factor was evaluated in a simple model. All variables were then entered into a full model, and a backward model building strategy was used to arrive at the final model. At each step in the model building, the least significant variable was removed from the model. The Quasi-likelihood Information Criteria (QICu) 31 was examined at each step to ensure that the reduced model was better than the previous model. The final model contained all variables that were statistically significant or needed in the model based on QICu criteria. The crude relative risk (RR) or adjusted RR (aRR) and corresponding 95% confidence interval (CI) are presented for each risk factor in the crude, full, and final models.
For the mortality following incident fracture analyses, covariates were obtained from study start (calendar years 2006-2008) except for filled prescriptions. Unadjusted and fully adjusted models, using a similar model building strategy defined above, are presented. Potential covariates included age, gender, race, ethnicity, BMI, CCI, osteoporosis, vitamin D deficiency, hyperparathyroidism, hypogonadism, multiple myeloma, medication use, dietary supplements, and a history of fracture 5 years before incident dialysis. 32 Hazard ratios (HR) and adjusted HR (aHR) with 95% CI are presented for each survival analysis.
All analyses were performed in SAS, version 9.4, SAS Institute (Cary, USA). Statistical significance was assessed using an alpha level of 0.05.
Results
There were 716 patients who had SLE and 4176 patients without SLE included in the analyses. The percent of patients with an incident fracture was 10.6% (n ¼ 76) in SLE compared to 12.1% (n ¼ 507) in controls (p ¼ 0.24). 89 total fractures occurred in patients with SLE and ESRD, including 69 site-specific fracture and 20 stress fractures. Of the site-specific fractures, hip fractures (n ¼ 29; 33%) outnumbered all other fractures; this was followed by fractures of the upper extremity (n ¼ 15; 17%), vertebrae (n ¼ 12; 13%), and lower extremity (n ¼ 13; 15%). In the control group (n ¼ 507), there were 588 fractures. Fractures of the hip (n ¼ 245; 42%) outnumbered those of the lower extremity (n ¼ 127; 22%), upper extremity (n ¼ 90; 15%), vertebrae (n ¼ 50; 8%), and stress fractures (n ¼ 76; 13%). Pharmacological treatment for osteoporosis was rarely used, with less than 10% of the study population on treatment with a bisphosphonate, estrogen, SERMs, or PTH. Similarly, magnesium and vitamin D supplements use was uncommon (less than 7% of the population), but calcium supplement use was common, with 45% of those with fractures taking calcium and 53% of those without fractures (data not shown). Table 1 demonstrates the baseline characteristics of patient with ESRD and SLE with and without fracture. Approximately 90% of those who had a fracture were female; 57% were white, while 43% were black. The majority of patients with a fracture were on hemodialysis (n ¼ 74, 97%) and relatively few were on peritoneal dialysis (n ¼ 2, 3%). The mean age at onset of dialysis in patients with a fracture was 61 years compared to 58 years in patients without a fracture (p ¼ 0.06). There were no significant differences between the groups in tobacco or alcohol use, BMI, CCI, osteoporosis, vitamin D deficiency, hyperparathyroidism, hypogonadism, multiple myeloma, prevalent fractures, use of any medications, or dietary supplements (p > 0.07 for all). Table 2 demonstrates the unadjusted and adjusted relative risk for incident fracture among patients with ESRD and SLE. In the full multivariable adjusted model, advanced age (aRR 1.02, 95% CI 1.01-1.04) was associated with increased fracture risk. Race, ethnicity, dialysis type, tobacco
and alcohol use, BMI, CCI, osteoporosis, vitamin D deficiency, hyperparathyroidism, hypogonadism, multiple myeloma, prevalent fractures, or medication use (corticosteroids, opioids, selective serotonin reuptake inhibitors, proton pump inhibitors, anticonvulsants, diuretics, sedatives, oral hypoglycemics, p > 0.07 for all) were not significantly associated with risk for fracture. The final model contained age at incident ESRD with an aRR of 1.02 (95% CI: 1.01-1.04, p ¼ 0.003) and indicates that among those with SLE, for every year individuals age, they are at increased risk of fracture. Use of calcium supplements was associated with a decreased risk for incident fracture (HR 0.63, 95% CI 0.40-0.99, data not shown); however, use of bisphosphonates, SERMs, estrogen, or PTH was not significantly associated with fracture risk (data not shown). As indicated previously, use was uncommon.
Incident fracture occurred in 11.1% (n ¼ 51) of patients with SLE who died compared to 9.8% (n ¼ 25) of patients who did not die (p ¼ 0.60). The Kaplan-Meier survival curve for all causes of mortality by site-specific fracture is shown in Figure 1 . Table 3 gives the unadjusted and final adjusted models for mortality. In fully adjusted models, the risk for mortality in patients with SLE and ESRD was close to tripled in those with incident vertebral fractures compared to those without fractures (aHR 2.71, 95% CI 1.71-4.31). Likewise, mortality more than doubled in patients with fractures at the hip (aHR 2.13, 95% CI 1.16-3.92). Among risk factors, advanced age (aHR 1.02, 95% CI 1.01-1.02) was significantly associated with mortality. 
Discussion
Osteoporotic fractures occur in a similar frequency in patients with SLE and ESRD compared with the general population of patients with ESRD. In patients with SLE and ESRD, advanced age at onset of dialysis is associated with an increased risk for fracture. Vertebral and hip fractures are associated with significantly increased mortality. In the USRDS, approximately 1 in 10 patients with SLE on dialysis incurred a fracture within 5 years of starting dialysis. This fracture rate was similar to that observed in patients without SLE. Previous case series in the general SLE population report fracture prevalences of 4.4%-42%. 1, 9, 10, 16, 33, 34 To our knowledge, this is the first report of the incidence of osteoporotic fractures in patients with SLE and ESRD. Although almost half of all fractures in patients with ESRD with and without SLE occurred at the hip, patients with SLE and ESRD had more vertebral fractures (13%) than those without SLE (8%), consistent with reports that vertebral fractures occur commonly in the general SLE population. 18, 35 In this series, older age at onset of dialysis was associated with increased risk for fracture. This finding is in accord with previous studies in the general population without ESRD, in which advanced age is a risk factor for low BMD and osteoporotic fracture, 2 and extends this to include Figure 1 Kaplan-Meier survival curve mortality in patients with SLE and ESRD by fracture status. 36 That type of dialysis was not a risk factor for fractures in patients with SLE and ESRD is in contrast with that of the general population of patients with ESRD, in which hemodialysis, compared with peritoneal dialysis, is a risk for fracture. 15, 37, 38 However, these results should be interpreted with caution as less than 3% of patients with SLE and ESRD were receiving peritoneal dialysis. No medication examined or secondary medical condition (hyperparathyroidism, multiple myeloma, hypogonadism, or vitamin D deficiency) was identified as an independent risk factor for fracture in SLE and ESRD, although secondary medical conditions were rarely identified. However, doses of corticosteroids were not included in the analysis, and in the general population of patients with SLE, cumulative doses of corticosteroids have been associated with fractures. 39 Although calcium supplementation was associated with a slightly decreased risk for fracture, there was no information on dose or preparation of calcium used, and use of calcium supplementation in ESRD should be approached with caution. 40 In patients with SLE and ESRD, vertebral and hip fractures were significant contributors to mortality. To our knowledge, there are no previous reports of the association of fractures with mortality in persons with SLE and ESRD. These findings are in accord with previous reports of increased mortality following both hip 38, 41 and vertebral 42 fractures in the general population with ESRD That use of vitamin D supplementation was associated with a decreased risk for mortality following fracture is consistent with reports in the general population without ESRD that low serum levels of vitamin D are associated with poorer outcomes following hip fracture. 43, 44 In the USRDS, black race (compared with whites) and Hispanic ethnicity were also associated with a decreased risk for mortality following fracture; this is consistent with recent studies of mortality following hip fracture in the general population without ESRD. 45, 46 We were surprised that corticosteroids and sedatives were also associated with decreased risk for mortality following fracture. While it has been suggested that corticosteroids may decrease the risk for fat embolism following fracture, 47 these are rare events and not likely to explain our findings. Further reports of the association of, in particular, corticosteroids, with mortality following fracture in ESRD are needed.
There are a number of limitations to this study. To start, only inpatient claims were utilized, and thus fractures that are less likely to incur hospitalizations, such as Colles fractures and asymptomatic vertebral fractures, may not be well captured. Medication data was not available prior to 2006 in the USRDS data obtained, and dose or duration of medications that were filled was not captured. In addition, the use of dietary supplements may be under-represented as they are available overthe-counter and may not have a coinciding prescriptions claim in the Medicare Part D dataset. Diagnosis of SLE was determined by an ICD-9 claim code, and it is unknown whether these individuals fulfilled the American College of Rheumatology classification criteria 48 for SLE. Thus, there is the potential for misclassification of disease state. Disease activity of SLE was not available. Finally, only patient data through 2011 in the USRDS were included as that is the last date we had complete records for.
This study also has a number of important strengths. To start, to our knowledge, this is the first report to address the issue of osteoporotic fractures in patients with SLE and ESRD. It includes a large cohort of patients with SLE of both genders and all races. This report is particularly timely, given the rising numbers of patients with SLE with ESRD.
In conclusion, the risk for osteoporotic fractures in patients with SLE and ESRD is similar to that of the general population with ESRD. Fracture prevention is important for patients with SLE and ESRD, as both vertebral and hip fractures are significant contributors to mortality in this population.
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